With Bydureon’s U.S. Approval, Amylin Extends Exenatide Franchise
This article was originally published in The Pink Sheet Daily
Executive Summary
Twice delayed by “complete response” letters, the drug’s approval gives Amylin a once-weekly GLP-1 analog, the longest-acting drug in its class.